Molecular analysis of structural abnormalities in papillary thyroid carcinoma genome

Molecular Biology

Volumn 38, Issue 4, 2004, Pages 538-548

  Vasil'ev, E V ^a   Roumiantsev, P O ^b   Saenko, V A ^b   Il'in, A A ^b   Polyakova, E Yu ^c   Nemtsova, M V ^a   Zaletayev, D V ^a  

^a RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

BRAF; papillary thyroid carcinoma; RET protooncogene; RET PTC chimeric oncogene

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN;

ARTICLE; CANCER GENETICS; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVATION; FOLLICULAR CARCINOMA; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; HUMAN TISSUE; NODULAR GOITER; PAPILLARY CARCINOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTO ONCOGENE; SOMATIC MUTATION; THYROID ADENOMA; THYROID CARCINOMA;

EID: 4444373936     PISSN: 00268933     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MBIL.0000037006.90193.f6     Document Type: Article

References (55)

1. Robbins J. 1991. Thyroid cancer, a lethal endocrine neoplasm. Ann. Intern. Med. 115, 133-147.
2. Farid N.R., Shi Y., Zou M. 1994. Molecular basis of thyroid cancer. Endocr. Rev. 15, 202-232.
3. Learoyd D.L., Messina M., Zedenius J., Robinson B.G. 2000. Molecular genetics of thyroid tumors and surgical decision-making. World J. Surg. 24, 923-933.
4. Goretzki P.E., Dotzenrath C., Simon D., Roher H.-D. 1999. Studies of oncogenes and tumor-suppressor genes in human thyroid carcinomas, and their clinical implications. Langenbeck's Arch. Surg. 384, 1-8.
5. Sarlis N.J. 2000. Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: Basic aspects. Rev. Endocr. Metab. Disorders. 1, 183-196.
6. Komminoth P. 1997. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Virchows Arch. 431, 1-9.
7. Nakamura T., Ishizaka Y., Nagao M., Ishikawa T. 1994. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J. Pathol. 172, 255-260.
8. Baloh R.H., Enomoto H., Johnson E.M., Milbrandt J. 2000. The GDNF family ligands and receptors: Implications for neural development. Curr. Opin. Neurobiol. 10, 103-110.
9. Eng C. 1999. RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17, 380-393.
10. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Dell Porta G., Fusco A., Vecchio G. 1990. PTC is a novel rearranged form of ret proto-oncogene and frequently detected in vivo in human thyroid papillary carcinomas. Cell. 60, 557-563.
11. Santoro M., Carlomagno F., Hay I.D., Herrmann M.A., Grieco M., Melillo R., Pierotti M.A., Bongarzone I., Della Porta G., Berger N., Peix, J.L., Paulin C., Fabien N., Vecchio G., Jenkins R.B., Fusco A. 1992. RET oncogene activation in thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89, 1517-1522.
12. Tallini G., Asa S.L. 2001. RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 8, 345-354.
13. Pierotti M.A., Santoro M., Jenkins R.B., Sozzi G., Bongarzone I., Grieco M., Monzini N., Miozzo M., Herrmann M.A., Fusco A., Hay I.D., Della Porta G., Vecchio G. 1992. Characterization of an inversion on the long arm of chromosome 10 juxtaposes D10S170 and ret and creating the oncogenic sequence Ret/PTC. Proc. Natl. Acad. Sci. USA. 89, 1616-1620.
14. Bongarzone I., Butti M.G., Coronelli S., Borrello M.G., Santoro M., Mondellini P., Pilotti S., Fusco A., Della Porta G., Pierotti M.A. 1994. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 54, 2979-2985.
15. Bongarzone I., Monzini N., Borrello M.G., Carcano C., Ferraresi G., Arighi E., Mondellini P., Della Porta G., Pierotti M.A. 1993. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of Ret tyrosine kinase and the regulatory subunit RI a of cyclic AMP-dependent protein kinase A. Mol. Cell Biol. 13, 358-366.
16. Tuttle R.M., Becker D.V. 2000. The Chernobyl and its consequences: Update at the millennium. Semin. Nucl. Med. 30, 133-140.
17. Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C., Della Porta G. 1992. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene. 7, 237-242.
18. Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M., Pierotti M.A. 1995. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell. Biol. 15, 6118-6127.
19. Pearson G., Robinson F., Gibson T.B., Xu B.-E., Karandikar M., Berman K., Cobb M.H. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev. 22, 153-183.
20. Suarez H.G., du Villard J.A., Severino M., Caillou B., Schlumberger M., Tubiana M., Parmentier C., Monier R. 1990. Presence of mutations of all three ras genes in human thyroid tumors. Oncogene. 5, 565-570.
21. Karga H., Lee J.-K., Vickery A.L., Thor A., Gaz R.D., Jameson J.L. 1991. Ras oncogene mutations in benign and malignant thyroid tumors. J. Clin. Endocr. Metab. 73, 832-836.
22. Rapp U.R., Goldsborough M.D., Mark G.E., Bonner T.I., Groffen J., Reynolds Jr. F.H., Stephenson J.R. 1983. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. USA. 80, 4218-4222.
23. Jansen H.W., Lurz R., Bister K., Bonner T.I., Mark G.E., Rapp U.R. 1984. Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature. 307, 281-284.
24. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. 2002. Mutations of the BRAF gene in human cancer. Nature. 417, 949-954.
25. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., Hauss J., Wittekind C. 2003. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 52, 706-712.
26. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., Maximo V., Botelho "., Seruca R., Sobrinho-Simões M. 2003. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 22, 4578-4580.
27. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. 2003. High prevalence of BRAF mutations in thyroid cancer. Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457.
28. Xu X., Quiros R.M., Gattuso P., Ain K.B., Prinz R.A. 2003. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567.
29. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., Sidransky D. 2003. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95, 625-627.
30. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., Saenko V.A., Kanematsu T., Yamashita S. 2003. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocr. Metab. 88, 4393-4397.
31. Fukushima T., Suzuki S., Mashiko M., Ohtake T., Endo Y., Takebayashi Y., Sekikawa K., Hagiwara K., Takenoshita S. 2003. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 22, 6455-6457.
32. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., Nikiforov Y.E. 2003. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404.
33. Landegren U. 1996. Laboratory Protocols for Mutation Detection. Oxford: Oxford Univ. Press.
34. Smanik P.A., Furminger T.L., Mazzaferri E.L., Jhiang S.M. 1995. Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Hum. Mol. Genet. 4, 2313-2318.
35. Bunone G., Uggeri M., Mondellini P., Pierotti M.A., Bongarzone I. 2000. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res. 60, 2845-2849.
36. Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E., Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A., Namba H., Tsyb A., Yamashita S. 2003. Novel tumorigenic rearrangement, delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient. Mutat. Res. 527, 81-90.
37. Takahashi M., Ritz J., Cooper G.M. 1985. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 42, 581-588.
38. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., Fagin J.A. 1997. Distinct pattern of ret oncogene rearrangement in morphological variants of radiation-induced and sporadic thyroid papillary thyroid carcinomas in children. Cancer Res. 57, 1690-1694.
39. Bongarzone I., Vigneri P., Mariani L., Collini P., Pilotti S., Pierotti M.A. 1998. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: Correlation with clinopathological features. Clin. Cancer Res. 4, 223-228.
40. Thomas G.A., Bunnell H., Cook H.A., Williams E.D., Nerovnya A., Cherstvoy E.D., Tronko N.D., Bogdanova T.I., Chiappetta G., Viglietto G., Pentimalli F., Salvatore G., Fusco A., Santoro M., Vecchio G. 1999. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: A strong correlation between RET/PTC3 and the solid-follicular variant. J. Clin. Endocr. Metab. 84, 4232-4238.
41. Cinti R., Yin L., Ilc K., Berger N., Basolo F., Cuccato S., Giannini R., Torre G., Miccoli P., Amati P., Romeo G., Corvi R. 2000. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet. Cell Genet. 88, 56-61.
42. Ishizaka Y., Kobayashi S., Ushijima T., Hirohashi S., Sugimura T., Nagao M. 1991. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene. 6, 1667-1672.
43. Sugg S.L., Ezzat S., Rosen I.B., Freeman J.L., Asa S.L. 1998. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocr. Metab. 83, 4116-4122.
44. Viglietto G., Chiappetta G., Martinez-Tello F.J., Fukunaga F.H., Tallini G., Rigopoulou D., Visconti R., Mastro A., Santoro M., Fusco A. 1995. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 11, 1207-1210.
45. Corvi R., Martinez-Alfaro M., Harach H.R., Zini M., Papotti M., Romeo G. 2001. Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization. Lab. Invest. 81, 1639-1645.
46. Harach H.R., Franssila K.O., Wasenius V.M. 1985. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 56, 531-538.
47. Newton C.R., Graham A., Heptinstall L.E., Powell S.J., Summers C., Kalsheker N., Smith J.C., Markham A.F. 1989. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17, 2503-2516.
48. Mercer K.E., Pritchard C.A. 2003. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta. 1653, 25-40.
49. Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J. 1997. Differential regulation of Raf-1, A-Raf and B-Raf by oncogenic Ras and tyrosine kinases. J. Biol. Chem. 272, 4378-4383.
50. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hosteller G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trenl J.M., Meltzer P.S. 2003. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19-20.
51. Flores J.F., Walker G.J., Glendening J.M., Haluska F.G., Castresana J.S., Rubio M.P., Paslorfide G.C., Boyer L.A., Kao W.H., Bulyk M.L., Barnhill R.L., Hayward N.K., Housman D.E., Fountain J.W. 1996. Loss of the p161NK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 56, 5023-5032.
52. Kumar R., Sauroja I., Punnonen K., Jansen C., Hemminki K. 1998. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer. 23, 273-277.
53. Zuo L., Weger J., Yang Q., Goldstein A.M., Tucker M.A., Walker G.J., Hayward N., Dracopoli N.C. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12, 97-99.
54. Lackey K., Cory M., Davis R., Frye S.V., Harris P.A., Hunter R.N., Jung D.K., McDonald O.B., McNutt R.W., Peel M.R., Rutkowske R.D., Veal J.M., Wood E.R. 2000. The discovery of potent cRaf 1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 223-226.
55. Kolch W. 2002. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert. Opin. Pharmacother. 3, 709-718.